Skip to main content
. 2022 Jun 28;4(8):100512. doi: 10.1016/j.xkme.2022.100512

Figure 1.

Figure 1

Participant dispositions in the pooled KALM-1 and KALM-2 studies. There were 2 participants in the placebo group and 3 participants in the difelikefalin group who discontinued due to a lack of eligibility after randomization.